Are you an SME interested in funding of Adverse Drug Reaction research through the European Commission's 7th Framework Programme?
26/07/2010 (updated 06/09/2010) - This message is targeted at service providers with expertise in the field of pharmacovigilance, pharmacoepidemiology and health outcome research and that qualify as micro, small and medium-sized enterprises (SMEs) interested in public funding of Adverse Drug Reaction research through the 7th Framework Programme (FP7).
The European Medicines Agency and the European Commission DG Research are organising a joint workshop on 13 September 2010 to raise awareness on the potential funding opportunities through the 7th Framework Programme for health research in 2011 and provide guidance to interested parties on the application procedure to be followed to facilitate applications from SMEs. The workshop will take place at the premises of the European Medicines Agency in Canary Wharf, London and is scheduled to start at 10:00 and conclude at approx. 16:00.
In order to qualify as SMEs, the definition of micro, small and medium-sized enterprises provided in Commission Recommendation 2003/361/EC will apply:
|Enterprise category||Headcount||Turnover||or||Balance sheet total|
|medium-sized||250||≤ € 50 million||≤ € 43 million|
|small||50||≤ € 10 million||≤ € 10 million|
|micro||10||≤ € 2 million||≤ € 2 million|
As regards the nature of the service providers, this workshop is particularly intended for but not limited to: Contract Research Organisations (CROs), service providers, academic spin-off companies, consultancies with a specific interest and work experience in the field of pharmacovigilance, pharmacoepidemiology, health outcome research, patient-reported outcomes, drug utilisation studies, etc. It is not intended for pharmaceutical companies (i.e. Marketing Authorisation Holders).
To register your participation in this workshop, please send by 8 September 2010 the following information by email to: email@example.com
- Contact name
- Name and address of organisation
- Brief description of activities covered
The 5th Health Call was published by the European Commission on 20 July 2010 (deadline for submission of proposals is 10 November 2010). Further information and all relevant documents can be found on the CORDIS website
Further information on the proposed priorities for adverse drug reaction research can be found at the ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) website at: http://www.encepp.eu/events/index.html